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Introduction
The National Survey of Nosocomial Infection Surveil-
lance (ENVIN) is a computerized record of the inci-
dence of nosocomial infection in ICU in Spain. In our
hospital, we have drafted rules for the maintenance of
the airway in mechanically ventilated patients following
general recommendations.
Objectives
Describe the clinical diagnosis and microbiology of VAP
after the implementation of the NZ program.
Methods
18 ICU beds. Data from ENVIN 01.04.11 / 01.04.15
(clinical diagnosis, microorganisms isolated and antibio-
tic resistance, inflammatory response ).
NZ: Educational campaign (presencial and by means
of internet) to professionals of our unit and anesthesia-
resuscitation unit (112 professionals). Were instituted
mandatory measures for the prevention of VAP.
Results
01.04.11/01.04.12- 15 VAP.- Clinical diagnosis:
support clinical radiological+new infiltrate 80%.
Extension of previous infiltrate + clinical worsening
(2nd pneumonia)20%- Germ:
A. baumanii 44.44%: resistance: amikacin, ampicilin,
imipenem, tobramicin
P. aeuroginosa 22.22%: resistance: amikacin, ceftaci-
dim, ciprofloxacin,




- Inflammatory response: sepsis 33.33%, severe sepsis
33.33%.
01.04.12/01.04.13-6 VAP- Diagn:
support clinical radiological+new infiltrate 66.67%
extension of previous infiltrate + clinical worsening
(2nd pneumonia) 16.67%,
CT 16.67%.- Germ:
S. Aureus 22 .22%: no resistance
S. Maltophilla 22.22% no resistance
Polymicrobial 50%.
Without diagnostic 16.67%
- Inflammatory response: sepsis 50%, severe sepsis
33.33%, shock 16.67%
01.04.13/01.04.14- 10 VAP- Diagn:
support clinical radiological+new infiltrate 60%




E. Coli 16.67%: resistance: ciprofloxacin, amox-clav.
H. Influnzae 8.33%








support clinical radiological+new infiltrate 68.57%
extension of previous infiltrate + clinical worsening
(2nd pneumonia) 22.86%
CT 8.57%.- Germ:Hospital Universitario San Cecilio, Unidad Cuidados Intensivos, Granada,
Spain
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A. baumanii 18.6% . Resistance: amikacin
P. aeuroginosa 16.28% . Resistance: amikacin, cefepime
S. aureus 13.95%: no resistance
Polimicrobial 28.57%
- Inflammatory response: sepsis 33.33%, severe sepsis
66.67%
Conclusions
Most of the diagnoses are made by the patient’s clinical
and x-ray. Each year vary germs being the most frequent
S. aureus and P. aeruginosa. Usually, the most common
inflammatory response is sepsis. The P. aeruginosa is
the germ which has more resistance.
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